These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 11675364)
1. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901 [TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Shaker S; Bernstein M; Momparler LF; Momparler RL Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295 [TBL] [Abstract][Full Text] [Related]
4. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220 [TBL] [Abstract][Full Text] [Related]
5. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520 [TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097 [TBL] [Abstract][Full Text] [Related]
7. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027 [TBL] [Abstract][Full Text] [Related]
8. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335 [TBL] [Abstract][Full Text] [Related]
9. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611 [TBL] [Abstract][Full Text] [Related]
10. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137 [TBL] [Abstract][Full Text] [Related]
11. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553 [TBL] [Abstract][Full Text] [Related]
17. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267 [TBL] [Abstract][Full Text] [Related]